Literature DB >> 2667837

The natural history of medication compliance in a drug trial: limitations of pill counts.

P Rudd1, R L Byyny, V Zachary, M E LoVerde, C Titus, W D Mitchell, G Marshall.   

Abstract

To assess medication compliance over time, we prospectively performed pill counts among 121 ambulatory hypertensive subjects for less than or equal to 12 months. Prescribed regimens consisted of pinacidil or hydralazine administered four times a day and of secondary drugs administered up to twice daily. Surreptitious pill counts occurred every 1 to 12 weeks. Among a middle-aged subject group that had been selected for high rates of compliance, we observed mean compliance rates that approximated 100%. We noted marked intrasubject and intersubject variability for any one medication, between medications, and over time. From baseline blood pressures (+/- SE) of 155.5 +/- 1.9/97.3 +/- 1.0 mm Hg, subsequent mean blood pressures varied by compliance subgroup: "hypocompliers" (less than 80%), 151.3/91.0 mm Hg; "hypercompliers" (greater than or equal to 120%), 147.6/91.4 mm Hg; and "eucompliers" (80% to 119%), 143.3/88.5 mm Hg (systolic blood pressure: F1,52 = -220.9, NS; diastolic blood pressure: F1,52 = -121.4, NS). We concluded that weekly pill counts indicated marked intersubject and intrasubject variability, obscured by long-term averages; that compliance lapses appeared to be random; and that excessive medication-taking was the most consistent with "pill dumping."

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2667837     DOI: 10.1038/clpt.1989.122

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  44 in total

Review 1.  Accounting for noncompliance in pharmacoeconomic evaluations.

Authors:  D A Hughes; A Bagust; A Haycox; T Walley
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  A comparison of a short half-life marker (low-dose isoniazid), a long half-life pharmacological indicator (low-dose phenobarbitone) and measurements of a controlled release 'therapeutic drug' (metoprolol, Metoros) in reflecting incomplete compliance by volunteers.

Authors:  E Hardy; S Kumar; S Peaker; M Feely; T Pullar
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

Review 3.  From compliance to concordance in diabetes.

Authors:  J S Chatterjee
Journal:  J Med Ethics       Date:  2006-09       Impact factor: 2.903

4.  Medication compliance during a smoking cessation clinical trial: a brief intervention using MEMS feedback.

Authors:  Joy M Schmitz; Shelly L Sayre; Angela L Stotts; Jennifer Rothfleisch; Marc E Mooney
Journal:  J Behav Med       Date:  2005-04

Review 5.  Practical and conceptual challenges in measuring antiretroviral adherence.

Authors:  Karina M Berg; Julia H Arnsten
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

6.  Measurement of patient compliance and the interpretation of randomized clinical trials.

Authors:  R Vander Stichele
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 7.  Assessing medication adherence in the elderly: which tools to use in clinical practice?

Authors:  Eric J MacLaughlin; Cynthia L Raehl; Angela K Treadway; Teresa L Sterling; Dennis P Zoller; Chester A Bond
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

8.  Compliance with drug therapy.

Authors:  T Pullar
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

Review 9.  The implications of noncompliance with antihypertensive medication.

Authors:  B Girvin; G D Johnston
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

10.  Compliance with medication in the Helsinki Heart Study.

Authors:  H Mäenpää; V Manninen; O P Heinonen
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.